Which sources of flavonoids: Complex diets or dietary supplements?

Advances in Nutrition

Volumn 2, Issue 1, 2011, Pages 8-14

  Egert, Sarah ^a   Rimbach, Gerald ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FLAVONOID;

ANIMAL; CACAO; COMPARATIVE STUDY; DIET; DIET SUPPLEMENTATION; DRUG INTERACTION; FRUIT; HEALTH PROMOTION; HUMAN; REVIEW; TEA; VEGETABLE;

ANIMALS; ANTIOXIDANTS; CACAO; DIET; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; FLAVONOIDS; FRUIT; HEALTH PROMOTION; HUMANS; TEA; VEGETABLES;

EID: 80053942110     PISSN: 21618313     EISSN: 21565376     Source Type: Journal    
DOI: 10.3945/an.110.000026     Document Type: Review

References (104)

1. WHO. The atlas of heart disease and stroke. Mackay J, Mensah GA, editors. Geneva: WHO; 2004.
2. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr. 2006;136:2588-93.
3. Nöthlings U, Schulze MB, Weikert C, Boeing H, van der Schouw YT, Bamia C, Benetou V, Lagiou P, Krogh V, et al. Intake of vegetables, legumes, and fruit, and risk for all-cause, cardiovascular, and cancer mortality in a European diabetic population. J Nutr. 2008;138:775-81.
4. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. 2006;367:320-6.
5. Pascual-Teresa S, Moreno DA, Garcia-Viguera C. Flavanols and anthocyanins in cardiovascular health: a review of current evidence. Int J Mol Sci. 2010;11:1679-703.
6. Pascual-Teresa S, Santos-Buelga C, Rivas-Gonzalo JC. Quantitative analysis of flavan-3-ols in Spanish foodstuffs and beverages. J Agric Food Chem. 2000;48:5331-7.
7. Hodgson JM. Effects of tea and tea flavonoids on endothelial function and blood pressure: a brief review. Clin Exp Pharmacol Physiol. 2006; 33:838-41.
8. Schewe T, Steffen Y, Sies H. How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys. 2008;476:102-6.
9. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003;57:904-8.
10. Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, Kaptchuk TJ, Eisenberg DM. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135:262-8.
11. Turner R, Baron T,Wolffram S, Minihane AM, Cassidy A, Rimbach G, Weinberg PD. Effect of circulating forms of soy isoflavones on the oxidation of low density lipoprotein. Free Radic Res. 2004;38:209-16.
12. Steffen Y, Jung T, Klotz LO, Schewe T, Grune T, Sies H. Protein modification elicited by oxidized low-density lipoprotein (LDL) in endothelial cells: protection by (-)-epicatechin. Free Radic Biol Med. 2007;42:955-70.
13. Park YC, Rimbach G, Saliou C, Valacchi G, Packer L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNFalpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett. 2000;465:93-7.
14. Rimbach G, Valacchi G, Canali R, Virgili F. Macrophages stimulated with IFN-gamma activate NF-kappa B and induce MCP-1 gene expression in primary human endothelial cells. Mol Cell Biol Res Commun. 2000;3:238-42.
15. Tribolo S, Lodi F, Connor C, Suri S, Wilson VG, Taylor MA, Needs PW, Kroon PA, Hughes DA. Comparative effects of quercetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. Atherosclerosis. 2008;197:50-6.
16. Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, Kobayashi M, Kanayama M, Uchida K, et al. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem. 2008;283:9424-34.
17. Ishizawa K, Izawa-Ishizawa Y, Ohnishi S, Motobayashi Y, Kawazoe K, Hamano S, Tsuchiya K, Tomita S, Minakuchi K, et al. Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells. J Pharmacol Sci. 2009;109:257-64.
18. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost. 2004;2:2138-45.
19. Leikert JF, Rathel TR, Wohlfart P, Cheynier V, Vollmar AM, Dirsch VM. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation. 2002;106:1614-7.
20. Schnorr O, Brossette T, Momma TY, Kleinbongard P, Keen CL, Schroeter H, Sies H. Cocoa flavanols lower vascular arginase activity in human endothelial cells in vitro and in erythrocytes in vivo. Arch Biochem Biophys. 2008;476:211-5.
21. Boesch-Saadatmandi C, Niering J, Minihane AM, Wiswedel I, Gardeman A, Wolffram S, Rimbach G. Impact of apolipoprotein E genotype and dietary quercetin on paraoxonase 1 status in apoE3 and apoE4 transgenic mice. Atherosclerosis. 2010;211:110-3.
22. Terra X, Montagut G, Bustos M, Llopiz N, Ardevol A, Blade C, Fernandez-Larrea J, Pujadas G, Salvado J, et al. Grape-seed procyanidins prevent low-grade inflammation by modulating cytokine expression in rats fed a high-fat diet. J Nutr Biochem. 2009;20:210-8.
23. Bursill CA, Abbey M, Roach PD. A green tea extract lowers plasma cholesterol by inhibiting cholesterol synthesis and upregulating the LDL receptor in the cholesterol-fed rabbit. Atherosclerosis. 2007;193:86-93.
24. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr. 2005;81:S243-55.
25. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:38-50.
26. Garcia-Alonso M, Minihane AM, Rimbach G, Rivas-Gonzalo JC, Pascual-Teresa S. Red wine anthocyanins are rapidly absorbed in humans and affect monocyte chemoattractant protein 1 levels and antioxidant capacity of plasma. J Nutr Biochem. 2009;20:521-9.
27. Boesch-Saadatmandi C, Egert S, Schrader C, Coumol X, Barouki R, Muller MJ, Wolffram S, Rimbach G. Effect of quercetin on paraoxonase 1 activity: studies in cultured cells, mice and humans. J Physiol Pharmacol. 2010;61:99-105.
28. Benavente-Garcia O, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and antiinflammatory activity. J Agric Food Chem. 2008;56:6185-205.
29. Rimbach G, Weinberg PD, Pascual-Teresa S, Alonso MG, Ewins BA, Turner R, Minihane AM, Botting N, Fairley B, et al. Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochim Biophys Acta 2004;1670:229-37.
30. Espin JC, Garcia-Conesa MT, Tomas-Barberan FA. Nutraceuticals: facts and fiction. Phytochemistry. 2007;68:2986-3008.
31. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007; 45:2179-205.
32. Erdman JW Jr, Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, Harnly J, Hollman P, Keen CL, et al. Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr. 2007;137:S718-37.
33. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130:S2073-85.
34. Cermak R. Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opin Drug Metab Toxicol. 2008;4:17-35.
35. Hider RC, Liu ZD, Khodr HH. Metal chelation of polyphenols. Methods Enzymol. 2001;335:190-203.
36. Anghileri LJ, Thouvenot P. Natural polyphenols-iron interaction: its biological importance. Biol Trace Elem Res. 2000;73:251-8.
37. Ren J, Meng S, Lekka C, Kaxiras E. Complexation of flavonoids with iron: structure and optical signatures. J Phys Chem B. 2008;112:1845-50.
38. Ullmann U, Haller J, Bakker GC, Brink EJ, Weber P. Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man. Phytomedicine. 2005;12:410-5.
39. Samman S, Sandstrom B, Toft MB, Bukhave K, Jensen M, Sorensen SS, Hansen M. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J Clin Nutr. 2001;73:607-12.
40. Ma Q, Kim EY, Han O. Bioactive dietary polyphenols decrease heme iron absorption by decreasing basolateral iron release in human intestinal Caco-2 cells. J Nutr. 2010;140:1117-21.
41. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr. 1999;81: 289-95.
42. Cook JD, Reddy MB, Hurrell RF. The effect of red and white wines on nonheme-iron absorption in humans. Am J Clin Nutr. 1995;61: 800-4.
43. Zijp IM, Korver O, Tijburg LB. Effect of tea and other dietary factors on iron absorption. Crit Rev Food Sci Nutr. 2000;40:371-98.
44. Sandberg AS. Bioavailability of minerals in legumes. Br J Nutr. 2002; 88 Suppl 3:S281-5.
45. Frejnagel S, Wroblewska M. Comparative effect of green tea, chokeberry and honeysuckle polyphenols on nutrients and mineral absorption and digestibility in rats. Ann Nutr Metab. 2010;56:163-9.
46. Record IR, McInerney JK, Dreosti IE. Black tea, green tea, and tea polyphenols. Effects on trace element status in weanling rats. Biol Trace Elem Res. 1996;53:27-43.
47. Augustin K, Frank J, Augustin S, Langguth P, Ohrvik V, Witthoft CM, Rimbach G, Wolffram S. Green tea extracts lower serum folates in rats at very high dietary concentrations only and do not affect plasma folates in a human pilot study. J Physiol Pharmacol. 2009;60:103-8.
48. Alemdaroglu NC, Wolffram S, Boissel JP, Closs E, Spahn-Langguth H, Langguth P. Inhibition of folic acid uptake by catechins and tea extracts in Caco-2 cells. Planta Med. 2007;73:27-32.
49. Alemdaroglu NC, Dietz U, Wolffram S, Spahn-Langguth H, Langguth P. Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm Drug Dispos. 2008;29:335-48.
50. Song J, Kwon O, Chen S, Daruwala R, Eck P, Park JB, Levine M. Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and glucose. J Biol Chem. 2002;277:15252-60.
51. Wiegand H, Boesch-Saadatmandi C, Wein S, Wolffram S, Frank J, Rimbach G. Dietary flavonoids do not affect vitamin E status in growing rats. J Anim Physiol Anim Nutr (Berl). 2010;94:307-18.
52. Augustin K, Blank R, Boesch-Saadatmandi C, Frank J, Wolffram S, Rimbach G. Dietary green tea polyphenols do not affect vitamin E status, antioxidant capacity and meat quality of growing pigs. J Anim Physiol Anim Nutr (Berl). 2008;92:705-11.
53. Frank J, George TW, Lodge JK, Rodriguez-Mateos AM, Spencer JP, Minihane AM, Rimbach G. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J Nutr. 2009;139:58-62.
54. Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Müller MJ. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr. 2008;138:1615-21.
55. Ferreira AC, Lisboa PC, Oliveira KJ, Lima LP, Barros IA, Carvalho DP. Inhibition of thyroid type 1 deiodinase activity by flavonoids. Food Chem Toxicol. 2002;40:913-7.
56. Chandra AK, De N. Goitrogenic/antithyroidal potential of green tea extract in relation to catechin in rats. Food Chem Toxicol. 2010;48:2304-11.
57. Milerova J, Cerovska J, Zamrazil V, Bilek R, Lapcik O, Hampl R. Actual levels of soy phytoestrogens in children correlate with thyroid laboratory parameters. Clin Chem Lab Med. 2006;44:171-4.
58. Bitto A, Polito F, Atteritano M, Altavilla D, Mazzaferro S, Marini H, Adamo EB, D'Anna R, Granese R, et al. Genistein aglycone does not affect thyroid function: results from a three-year, randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2010;95:3067-72.
59. Doerge DR, Sheehan DM. Goitrogenic and estrogenic activity of soy isoflavones. Environ Health Perspect. 2002;110 Suppl 3:349-53.
60. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee. Arterioscler Thromb Vasc Biol. 2006; 26:1689-92.
61. Cermak R, Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab. 2006;7:729-44.
62. Alvarez AI, Real R, Perez M, Mendoza G, Prieto JG, Merino G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci. 2010;99: 598-617.
63. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol. 2006;2:171-82.
64. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34:83-448.
65. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther. 1992;261:1195-9.
66. Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17 beta-estradiol. Eur J Drug Metab Pharmacokinet. 1995;20:219-24.
67. von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol. 2004;56:1039-44.
68. Tang BK, Kalow W. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4. Eur J Clin Pharmacol. 1995;47: 449-51.
69. Vree TB, Dammers E, Ulc I, Horkovics-Kovats S, Ryska M, Merkx I. Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers: gut hydrolysis of lovastatin is twice that of simvastatin. ScientificWorldJournal. 2003;3:1332-43.
70. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol. 2003;56:120-4.
71. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343-70.
72. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-81.
73. Cermak R, Wein S, Wolffram S, Langguth P. Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur J Pharm Sci. 2009;38:519-24.
74. Obermeier MT, White RE, Yang CS. Effects of bioflavonoids on hepatic P450 activities. Xenobiotica. 1995;25:575-84.
75. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993;35:431-6.
76. Tsyrlov IB, Mikhailenko VM, Gelboin HV. Isozyme-and speciesspecific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids. Biochim Biophys Acta. 1994;1205:325-35.
77. Zhai S, Dai R, Wei X, Friedman FK, Vestal RE. Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes. Life Sci. 1998;63:PL119-23.
78. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000;294:88-95.
79. Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy. 2006;26:1314-9.
80. Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers. Biochem Pharmacol. 1997;54:1195-203.
81. He M, Kunze KL, Trager WF. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug Metab Dispos. 1995;23: 659-63.
82. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45:127-32.
83. Zikria J, Goldman R, Ansell J. Cranberry juice and warfarin: when bad publicity trumps science. Am J Med. 2010;123:384-92.
84. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005;106:97-132.
85. Wang LQ, James MO. Inhibition of sulfotransferases by xenobiotics. Curr Drug Metab. 2006;7:83-104.
86. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006; 45:253-85.
87. Galijatovic A, Otake Y, Walle UK,Walle T. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells: potential role in carcinogen bioinactivation. Pharm Res. 2001;18:374-9.
88. Walle T, Otake Y, Galijatovic A, Ritter JK, Walle UK. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line Hep G2. Drug Metab Dispos. 2000; 28:1077-82.
89. Walle UK, Walle T. Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids-structural requirements. Drug Metab Dispos. 2002;30:564-9.
90. Sugatani J, Yamakawa K, Tonda E, Nishitani S, Yoshinari K, Degawa M, Abe I, Noguchi H, Miwa M. The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol. 2004;67:989-1000.
91. van der Logt EM, Roelofs HM, Nagengast FM, PetersWH. Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. Carcinogenesis. 2003;24:1651-6.
92. Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos. 2003;31:805-13.
93. Walle T, Eaton EA, Walle UK. Quercetin, a potent and specific inhibitor of the human P-form phenosulfotransferase. Biochem Pharmacol. 1995;50:731-4.
94. De Santi C, Pietrabissa A, Mosca F, Rane A, Pacifici GM. Inhibition of phenol sulfotransferase (SULT1A1) by quercetin in human adult and foetal livers. Xenobiotica. 2002;32:363-8.
95. Marchetti F, De Santi C, Vietri M, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Differential inhibition of human liver and duodenum sulphotransferase activities by quercetin, a flavonoid present in vegetables, fruit and wine. Xenobiotica. 2001;31:841-7.
96. Eaton EA, Walle UK, Lewis AJ, Hudson T, Wilson AA, Walle T. Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos. 1996;24:232-7.
97. Vietri M, Vaglini F, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulfation of R(-)-apomorphine in the human liver and duodenum, and its inhibition by mefenamic acid, salicylic acid and quercetin. Xenobiotica. 2002;32:587-94.
98. Wiegand H, Boesch-Saadatmandi C, Regos I, Treutter D, Wolffram S, Rimbach G. Effects of quercetin and catechin on hepatic glutathione-S transferase (GST), NAD(P)H quinone oxidoreductase 1 (NQO1), and antioxidant enzyme activity levels in rats. Nutr Cancer. 2009;61:717-22.
99. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 2006;78:2116-30.
100. Brand W, Schutte ME, Williamson G, van Zanden JJ, Cnubben NH, Groten JP, van Bladeren PJ, Rietjens IM. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother. 2006;60:508-19.
101. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002;22:19-34.
102. Duthie GG, Gardner PT, Kyle JA. Plant polyphenols: are they the new magic bullet? Proc Nutr Soc. 2003;62:599-603.
103. Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002; 39:1083-95.
104. Poppenga RH. Risks associated with the use of herbs and other dietary supplements. Vet Clin North Am Equine Pract. 2001;17:455-77, vi-vii.